COGT
Price
$39.16
Change
+$0.18 (+0.46%)
Updated
Dec 3 closing price
Capitalization
6.01B
103 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$10.31
Change
+$0.31 (+3.10%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
761.68M
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COGT vs REPL

Header iconCOGT vs REPL Comparison
Open Charts COGT vs REPLBanner chart's image
Cogent Biosciences
Price$39.16
Change+$0.18 (+0.46%)
Volume$2.37M
Capitalization6.01B
Replimune Group
Price$10.31
Change+$0.31 (+3.10%)
Volume$21.54K
Capitalization761.68M
COGT vs REPL Comparison Chart in %
COGT
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
COGT vs. REPL commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Buy and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (COGT: $38.95 vs. REPL: $10.02)
Brand notoriety: COGT and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 52% vs. REPL: 60%
Market capitalization -- COGT: $6.01B vs. REPL: $809.54M
COGT [@Biotechnology] is valued at $6.01B. REPL’s [@Biotechnology] market capitalization is $809.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • COGT’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both COGT and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 3 bullish TA indicator(s).

  • COGT’s TA Score: 5 bullish, 4 bearish.
  • REPL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, COGT is a better buy in the short-term than REPL.

Price Growth

COGT (@Biotechnology) experienced а -1.94% price change this week, while REPL (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

COGT is expected to report earnings on Mar 17, 2026.

REPL is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($6.01B) has a higher market cap than REPL($762M). COGT YTD gains are higher at: 399.359 vs. REPL (-17.258). REPL has higher annual earnings (EBITDA): -268.18M vs. COGT (-299.34M). REPL has more cash in the bank: 403M vs. COGT (238M). COGT has less debt than REPL: COGT (60.7M) vs REPL (76.3M). COGT (0) and REPL (0) have equivalent revenues.
COGTREPLCOGT / REPL
Capitalization6.01B762M788%
EBITDA-299.34M-268.18M112%
Gain YTD399.359-17.258-2,314%
P/E RatioN/AN/A-
Revenue00-
Total Cash238M403M59%
Total Debt60.7M76.3M80%
FUNDAMENTALS RATINGS
COGT vs REPL: Fundamental Ratings
COGT
REPL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
20100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3441
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for COGT (82) in the Miscellaneous industry. This means that REPL’s stock grew somewhat faster than COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (20) in the Miscellaneous industry is significantly better than the same rating for REPL (100) in the Biotechnology industry. This means that COGT’s stock grew significantly faster than REPL’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as COGT (99) in the Miscellaneous industry. This means that REPL’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (34) in the Miscellaneous industry is in the same range as REPL (41) in the Biotechnology industry. This means that COGT’s stock grew similarly to REPL’s over the last 12 months.

COGT's P/E Growth Rating (100) in the Miscellaneous industry is in the same range as REPL (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTREPL
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
89%
Momentum
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 7 days ago
75%
MACD
ODDS (%)
Bullish Trend 7 days ago
85%
Bearish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 7 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
84%
Bearish Trend 7 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
82%
Bearish Trend 17 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 7 days ago
87%
Aroon
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
COGT
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOFX76.86N/A
N/A
Hartford Growth Opportunities F
PGWAX103.82N/A
N/A
Virtus Silvant Focused Growth A
AGSCX6.91N/A
N/A
Alger Small Cap Growth C
CLTCX16.74N/A
N/A
Catalyst/Lyons Tactical Allocation C
GHAYX49.68N/A
N/A
VanEck Global Resources Fund Y

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-2.04%
SPHDF - COGT
63%
Loosely correlated
N/A
ENGN - COGT
47%
Loosely correlated
-0.32%
GLTO - COGT
45%
Loosely correlated
+7.37%
RNAC - COGT
42%
Loosely correlated
-7.95%
REPL - COGT
42%
Loosely correlated
+3.19%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with NEVPF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+3.19%
NEVPF - REPL
64%
Loosely correlated
N/A
ELVAF - REPL
60%
Loosely correlated
N/A
IMNN - REPL
57%
Loosely correlated
+0.76%
SNDX - REPL
49%
Loosely correlated
-1.67%
KYMR - REPL
45%
Loosely correlated
-3.80%
More